Celldex Therapeutics

Celldex Therapeutics CLDX Stock

$31.65   -1.646990%
Add to favorites
Market Cap
$2.49B
LOW - HIGH [24H]
$30.98 - $32.54
VOLUME [24H]
$2.37M
P/E Ratio
0
Earnings per share
-$4.35
ISIN
US15117B2025
Price   Prediction

Celldex Therapeutics Price Chart

Sorry, that's all we've gotfor now...

Celldex Therapeutics CLDX Financial and Trading Overview

Celldex Therapeutics stock price 31.65 USD
Previous Close 31.49 USD
Open 31.49 USD
Bid 26.84 USD x 100
Ask 35.8 USD x 100
Day's Range 31 - 31.79 USD
52 Week Range 22.1 - 45.14 USD
Volume 2.03M USD
Avg. Volume 1.21M USD
Market Cap 2.48B USD
Beta (5Y Monthly) 0.84
PE Ratio (TTM) N/A
EPS (TTM) -4.35 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 63.07 USD

CLDX Valuation Measures

Enterprise Value 1.76B USD
Trailing P/E N/A
Forward P/E -7.468182
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 15725.788
Price/Book (mrq) 3.4757774
Enterprise Value/Revenue 11140.582
Enterprise Value/EBITDA -5.459

Trading Information

Celldex Therapeutics Stock Price History

Beta (5Y Monthly) 0.84
52-Week Change 21.72%
S&P500 52-Week Change 14.87%
52 Week High 45.14 USD
52 Week Low 22.1 USD
50-Day Moving Average 38.56 USD
200-Day Moving Average 32.25 USD

CLDX Share Statistics

Avg. Volume (3 month) 1.21M USD
Avg. Daily Volume (10-Days) 2.89M USD
Shares Outstanding 78.53M
Float 73.02M
Short Ratio 12.63
% Held by Insiders 0.27%
% Held by Institutions 110.27%
Shares Short 8.95M
Short % of Float 13.53%
Short % of Shares Outstanding 11.39%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:15

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) June 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -366468.19%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -27.61%
Return on Equity (ttm) -43.87%

Income Statement

Revenue (ttm) 158K USD
Revenue Per Share (ttm) 0.002 USD
Quarterly Revenue Growth (yoy) -97.00000000000000000000000000000000%
Gross Profit (ttm) -278648992 USD
EBITDA -322432000 USD
Net Income Avi to Common (ttm) -300548992 USD
Diluted EPS (ttm) -4.35
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 717.59M USD
Total Cash Per Share (mrq) 9.14 USD
Total Debt (mrq) 4.9M USD
Total Debt/Equity (mrq) 0.69 USD
Current Ratio (mrq) 11.821
Book Value Per Share (mrq) 9.103

Cash Flow Statement

Operating Cash Flow (ttm) -235566000 USD
Levered Free Cash Flow (ttm) -133080496 USD

Profile of Celldex Therapeutics

Country United States
State NJ
City Hampton
Address Perryville III Building
ZIP 08827
Phone 908 200 7500
Website https://www.celldex.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 198

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Q&A For Celldex Therapeutics Stock

What is a current CLDX stock price?

Celldex Therapeutics CLDX stock price today per share is 31.65 USD.

How to purchase Celldex Therapeutics stock?

You can buy CLDX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Celldex Therapeutics?

The stock symbol or ticker of Celldex Therapeutics is CLDX.

Which industry does the Celldex Therapeutics company belong to?

The Celldex Therapeutics industry is Biotechnology.

How many shares does Celldex Therapeutics have in circulation?

The max supply of Celldex Therapeutics shares is 78.53M.

What is Celldex Therapeutics Price to Earnings Ratio (PE Ratio)?

Celldex Therapeutics PE Ratio is now.

What was Celldex Therapeutics earnings per share over the trailing 12 months (TTM)?

Celldex Therapeutics EPS is -4.35 USD over the trailing 12 months.

Which sector does the Celldex Therapeutics company belong to?

The Celldex Therapeutics sector is Healthcare.

Celldex Therapeutics CLDX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.symbol }} {{ item.name }} {{ item.symbol }} {{ item.country.toUpperCase() }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
us US Tech Composite IXIC US 27190.86 USD —
+1.19
6.86B USD — 27112.24 USD — 27353.68 USD — — 6.86B USD —
us US Tech Biotechnology Total Retu XNBI US 7591.3 USD —
-0.26
— — 7558.42 USD — 7646.87 USD — — — —
us US Tech Capital Market Composite RCMP US 129.21 USD —
+0.44
— — 128.98 USD — 131.03 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3944.69 USD —
+1.09
— — 3936.74 USD — 3965.98 USD — — — —
us US Tech Health Care IXHC US 1302.61 USD —
-0.29
— — 1298.55 USD — 1311.62 USD — — — —
us US Tech Composite Total Return XCMP US 33588.44 USD —
+1.19
— — 33491.32 USD — 33789.56 USD — — — —
us US Tech US 700 Small Cap Index NQUS700SC US 3023.23 USD —
+0.65
— — 3020.05 USD — 3049.99 USD — — — —
$2.9T
Total marketcap
$81.35B
Total volume
BTC 58.74%   •   ETH 11.28%
Dominance
Select currency